Answers are grounded in this paper and cite their sources.
Introduction CAH is a rare autosomal recessive disorder predominantly caused by an enzyme deficiency that results in defective cortisol biosynthesis. This impairs negative feedback on the hypothalamus-pituitary-adrenal axis, leading to elevated ACTH and thus an excess of adrenal androgens. Although supraphysiologic glucocorticoids are commonly used to manage hyperandrogenemia, they are associated with long-term adverse effects. Asedebart is a novel, high-affinity, anti-ACTH monoclonal antibody that inhibits ACTH-induced signaling and has been shown to significantly and durably reduce corticosterone and aldosterone concentrations in rats, and cortisol and aldosterone concentrations in cynomolgus monkeys. Here we present preliminary, first-in-human findings on the safety, tolerability, pharmacokinetics, and pharmacodynamics of asedebart from a Phase I trial in adult patients with classic CAH. Methods This open-label, multiple-ascending-dose, 2-part trial (NCT05669950) enrolled men and women, aged 18-70 years, with classic CAH and pre-glucocorticoid morning 17-hydroxyprogesterone (17-OHP) concentrations >4 times the upper limit of normal. Participants received up to 6 doses of asedebart at increasing levels, every 28-35 days. Stable glucocorticoids and mineralocorticoid replacement were given. Part A of the trial consisted of a 3 + 3 design: 3 participants received a certain dose level and were escalated to the next dose level, following a 28-day safety observation period. Part B investigated the doses of asedebart which were identified as pharmacologically relevant during Part A, in a larger number of participants. Primary endpoints included adverse events, clinical safety, maximum observed exposure (in a dosing interval), area under the concentration–time curve (in a dosing interval), and relative reductions in morning 17-OHP and androstenedione (A4) concentrations (from baseline to the day following each asedebart dose). Results Eleven participants (7 women and 4 men) were enrolled, with a mean age of 37 years (range 21-58 years). At the baseline visit, mean (standard deviation) concentrations were 245.3 nmol/L (2.37 nmol/L) for morning 17-OHP and 10.4 nmol/L (2.28 nmol/L) for morning A4. Clear pharmacodynamic effects were observed in the 11 participants following up to 6 intravenous infusions of asedebart at increasing doses, and morning 17-OHP and A4 concentrations were reduced by 90.5%-98.7% and 66.3%-89.3%, respectively, across all dose levels. There were no safety concerns. Conclusions These preliminary Phase I results show that the anti-ACTH monoclonal antibody asedebart is well tolerated and can significantly reduce adrenal androgen production, supporting continued clinical development of asedebart as a promising treatment strategy for classic CAH.
No takes yet. Share an insight, caveat, or question.
Johannsson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: